Landos Biopharma (Landos Biopharma) Interest Expense : $-0.66 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Landos Biopharma's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.66 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Landos Biopharma's Operating Income for the three months ended in Dec. 2023 was $ -6.61 Mil. Landos Biopharma's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Landos Biopharma has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Landos Biopharma Interest Expense Historical Data

The historical data trend for Landos Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma Interest Expense Chart

Landos Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.30

Landos Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial														-	-	-	-0.66	-

Landos Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.66 Mil.

Landos Biopharma (NAS:LABP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Landos Biopharma's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-6.61 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

Landos Biopharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Landos Biopharma had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Landos Biopharma (Landos Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 11239, Blacksburg, VA, USA, 24060

Website

https://www.landosbiopharma.com

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.

Executives

Alka Batycky	director	C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi	officer: Chief Medical Officer	C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes	director, officer: Chief Executive Officer	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell	officer: Vice President and Controller	C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera	director, 10 percent owner, officer: Chairman, President and CEO	1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar	officer: Interim CFO	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003